AbbVie Inc (ABBV)vsArriVent BioPharma, Inc. Common Stock (AVBP)
ABBV
AbbVie Inc
$257.60
-2.16%
HEALTHCARE · Cap: $447.53B
AVBP
ArriVent BioPharma, Inc. Common Stock
$30.04
+0.20%
HEALTHCARE · Cap: $1.31B
Smart Verdict
WallStSmart Research — data-driven comparison
ABBV leads profitability with a 5.8% profit margin vs 0.0%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
AVBP
Avoid26
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-78.8%
Fair Value
$147.26
Current Price
$257.60
$110.34 premium
Intrinsic value data unavailable for AVBP.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Generating 3.6B in free cash flow
Conservative balance sheet, low leverage
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.42 suggests the stock is reasonably priced for its growth.
Bull Case : AVBP
The strongest argument for AVBP centers on Debt/Equity.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 124.8x leaves little room for execution misses.
Bear Case : AVBP
The primary concerns for AVBP are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
AVBP carries more volatility with a beta of 1.30 — expect wider price swings.
ABBV is growing revenue faster at 12.4% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (63/100 vs 26/100) and 12.4% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
ArriVent BioPharma, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
ArriVent BioPharma, Inc. (AVBP) is an innovative biopharmaceutical company committed to advancing groundbreaking therapies for critical unmet needs in oncology and autoimmune diseases. Leveraging proprietary technologies and a robust scientific foundation, ArriVent is focused on delivering improved patient outcomes through its promising pipeline. With strategic positioning in high-growth sectors of the biopharma industry, the company represents an attractive investment opportunity for institutional investors seeking to capitalize on transformative healthcare advancements with the potential for significant market impact.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?